XTLB XTL Biopharmaceuticals ADRs

XTL Biopharmaceuticals Ltd is engaged in the acquisition & development of pharmaceutical drugs for the treatment of unmet medical needs, currently for the treatment of schizophrenia and Hepatitis C. It has also developed a home therapeutic device. This is an ADR of a company whose stock trades outside of the U.S. as the symbol IT:XTLB.

$1.35  -0.11 (-7.54%)
As of 11/21/2022 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  Israel
IPO date:  02/18/2014
Outstanding shares:  5,449,062
Average volume:  6,940
Market cap:   $7,355,689
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%